Crick — Clinical Intelligence Platform

Large-scale testing (Phase 3)WithdrawnNCT07342517

What this trial is testing

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Who this might be right for

Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more

Relmada Therapeutics, Inc.

Results for “Urinary Bladder Urothelial Carcinoma”

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Tumor Budding and T1 Substaging in Urothelial Bladder Cancer

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Markers of Response to Intravesical Bladder Cancer Therapy

Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.

Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder